Overview MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) Status: Terminated Trial end date: 2009-05-20 Target enrollment: Participant gender: Summary A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.